http://www.logistiklink.de/i/user_detail.php?u=Tubbipbop
IPierian Inc., a South San Franciscoo company formed with the merger oftwo venture-backec startups, will focus on manipulatinv mature stem cells into ones with embryonic-like qualitiews that can be used to trear neurodegenerative problems like Lou Gehrig’sd disease. The new company is backed by a fresyh roundof $10 million from and $1.5 million from . — supported by $20 million from and and Pierian Inc. announcesd the merger on the eve ofthis week’s Internationall Stem Cell meeting in Barcelona.
Pierian was founder by MPM Capital managing directors Ashley Dombkowskiu and Robert Millman and IPierian — the new company — will be lead by iZumki CEO John Walker, with former executivs Corey Goodman as IPierian will focus on so-called inducef pluripotent stem cells for patients with difficult-to-treat neurodegenerative diseases, like Parkinson’s disease, spinal muscular atrophy and amyotrophic lateral sclerosis, or Lou Gehrig’s disease. Longefr term, the company will explor metabolic diseases, cardiovascular diseases and othertherapeutic areas.
“Disease-specific pluripotent stem cells are powerfu new tools for drug screeningy and promise to revolutionize the treatment ofintractable conditions,” said Dr. George Daley, who along with fello w Harvard faculty members Douglas Melton and Lee Rubih were the scientific foundersof IPierian’s scientific advisory board will be led by director of stem cell transplantation at the and at , and Dr. Deepal Srivastava, director of the in San Francisco. Among others on the scientifixc advisory boardare Goodman, who until May headed in Southu San Francisco; Dr. Lennart Mucke, director of the ; Dr.
Benoit an associate investigator at the Gladstone Institute of Cardiovascular and Dr. Matthias associate director for research at the diabetex center atthe , San Francisco. Mucke and Bruneau also are professorse atUCSF — Mucke in neurologyg and neuroscience and Bruneau and Srivastavaa in the pediatrics department. IPierian’s management includes Walker, chievf technology officer Dr. Berta Strulovici, and Dr. Dushyant who will lead business development. IZumi, formed last year by Kleinefr PerkinsCaufield & Byers and Highland Capital has collaborations with the and the Centert for iPS Cell Research and Application at Japan’zs , where Dr.
Shinya Yamanakza first succeeded in reprogramming adult cellzs in a mouse to becomelike embryonic-like. Yamanaka also works part time at the Gladstoned Institutesand UCSF. Embryonic stem cellas are the gold standard of stem cell researcy because theyare pluripotent, capablde of developing into heart, muscle, skin or other cells. Induced pluripotent like those createdby Yamanaka, are seen by many as a way to sideste p ethical and political issues associateed with extracting stem cells from but others say they can cause cancere in mice if any of the genes used to reprogra the cells remain active.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment